OriGene Technologies, Inc.
9620 Medical Center Drive, Ste 200
Rockville, MD 20850, US
Phone: +1-888-267-4436
https://www.origene.com
techsupport@origene.com
EU: info-de@origene.com
CN: techsupport@origene.cn

Product datasheet for TR311432

MNDA Human shRNA Plasmid Kit (Locus ID 4332)

Product data:

Product Type:	shRNA Plasmids
Product Name:	MNDA Human shRNA Plasmid Kit (Locus ID 4332)
Locus ID:	4332
Synonyms:	PYHIN3
Vector:	pRS (TR20003)
E. coli Selection:	Ampicillin
Mammalian Cell Selection:	Puromycin
Format:	Retroviral plasmids
Components:	MNDA - Human, 4 unique 29mer shRNA constructs in retroviral untagged vector(Gene ID = 4332). 5µg purified plasmid DNA per construct 29-mer scrambled shRNA cassette in pRS Vector, TR30012, included for free.
RefSeq:	NM_002432, NM_002432.1, NM_002432.2, BC032319, BC032319.1, BC020715, NM_002432.3
UniProt ID:	P41218
Summary:	The myeloid cell nuclear differentiation antigen (MNDA) is detected only in nuclei of cells of the granulocyte-monocyte lineage. A 200-amino acid region of human MNDA is strikingly similar to a region in the proteins encoded by a family of interferon-inducible mouse genes, designated Ifi-201, Ifi-202, and Ifi-203, that are not regulated in a cell- or tissue-specific fashion. The 1.8-kb MNDA mRNA, which contains an interferon-stimulated response element in the 5-prime untranslated region, was significantly upregulated in human monocytes exposed to interferon alpha. MNDA is located within 2,200 kb of FCER1A, APCS, CRP, and SPTA1. In its pattern of expression and/or regulation, MNDA resembles IFI16, suggesting that these genes participate in blood cell-specific responses to interferons. [provided by RefSeq, Jul 2008]
shRNA Design:	These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com. If you need a special design or shRNA sequence, please utilize our custom shRNA service.

View online »

Performance Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).